Form 8-K ALNYLAM PHARMACEUTICALS, For: Aug 10
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Alnylam Pharmaceuticals (ALNY) PT Lowered to $125 at BMO Capital; Onpattro U.S. Approval Lacks Benefit From Cardiac Data
August 13, 2018 6:35 AM EDTBMO Capital analyst Do Kim lowered the price target on Alnylam Pharmaceuticals (NASDAQ: ALNY) to $125.00 (from $127.00) while maintaining an Outperform rating saying the Onpattro U.S. approval lacks benefit from cardiac data.
"We believe the label's lack of cardiac data will... More
